VERO (R) radiotherapy for low burden cancer: 789 patients with 957 lesions

Purpose: The aim of this retrospective study is to evaluate patient profile, feasibility, and acute toxicity of RadioTherapy (RT) delivered by VERO\uae in the first 20 months of clinical activity. Methods: Inclusion criteria: 1) adult patients; 2) limited volume cancer (M0 or oligometastatic); 3) small extracranial lesions; 4) treatment between April 2012 and December 2013 and 5) written informed consent. Two techniques were employed: intensity modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT). Toxicity was evaluated using Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) criteria. Results: Between April 2012 and December 2013, 789 consecutive patients (957 lesions) were treated. In 84% of them one lesion was treated and in 16% more than one lesion were treated synchronously/metachronously; first radiotherapy course in 85%, re-irradiation in 13%, and boost in 2% of cases. The treated region included pelvis 46%, thorax 38%, upper abdomen 15%, and neck 1%. Radiotherapy schedules included <5 and >5 fractions in 75% and 25% respectively. All patients completed the planned treatment and an acceptable acute toxicity was observed. Conclusions: RT delivered by VERO\uae was administrated predominantly to thoracic and pelvic lesions (lung and urologic tumours) using hypofractionation. It is a feasible approach for limited burden cancer offering short and well accepted treatment with favourable acute toxicity profile. Further investigation including dose escalation and other available VERO\uae functionalities such as real-time dynamic tumour tracking is warranted in order to fully evaluate this innovative radiotherapy system

Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)

objective: To evaluate high-precision external beam reirradiation (re-EBRT) for local relapse of prostate cancer (PCa) after radiotherapy. Methods: This retrospective study included patients with biochemical failure and evidence of isolated local recurrence of PCa after radical/salvage EBRT or brachytherapy that received salvage stereotactic body radiation therapy (SBRT, re-EBRT). Biopsy was not mandatory if all diagnostic elements were univocal (prostate specific antigen evolution, choline-positron emission tomography or magnetic resonance imaging). Salvage SBRT (re-EBRT) was delivered with image-guided radiation therapy (RapidArc\uae, VERO\uae and CyberKnife\uae). results: Data of 64 patients were included, median age at salvage SBRT was 73.2 years, median pre-salvage SBRT prostate specific antigen was 3.89 ng ml 121 . Median total dose was 30 Gy in five fractions, biologically effective dose (BED) of 150 Gy. One acute G3 genitourinary event and one late G3 genitourinary event were observed. No G 65 3 bowel toxicity was registered. At the median follow-up of 26.1 months, tumor progression was observed in 41 patients (64%). 18 patients (28%) experienced local relapse. 2-year local control, biochemical and clinical relapse free survival rates were 75, 40 and 53%, respectively. With BED 65130 Gy 1-year biochemical and clinical progression-free survival rate were 85 and 90%, respectively. conclusions: Salvage SBRT (re-EBRT) for isolated local PCa recurrence is a safe, feasible and noninvasive salvage treatment. Further investigation is warranted to define the optimal patient selection, dose and volume parameters. advances in knowledge: Salvage SBRT reirradiation for the locally recurrent PCa offer a satisfactory tumor control and excellent toxicity profile, if BED 65130 Gy is administered

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

MicroRNA-155-5p (miR-155-5p) is a proinflammatory, oncogenic miRNA, involved in various physiological processes, including hematopoiesis, immunity, inflammation, and cell lineage differentiation. It regulates important transcription factors, such as E2F2, hypoxia-inducible factor 1 (HIF1), and FOXO3. Recently, the dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis. In this research study, we investigated the potential diagnostic and prognostic value of miR-155-5p in CLL. To achieve our goal, we isolated total RNA from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 nonleukemic blood donors and performed polyadenylation of total RNA and reverse transcription. Next, we quantified miR-155-5p levels using an in-house-developed real-time quantitative PCR method, before proceeding to extensive biostatistical analysis. Thus, it appears that miR-155-5p is significantly overexpressed in PBMCs of CLL patients and can distinguish them from nonleukemic population. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-155-5p expression predicts inferior OS for CLL patients (p<0.001). Interestingly, miR-155-5p overexpression retains its unfavorable prognostic role in CLL patients stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable region (IGHV)]. Thus, miR-155-5p appears as a promising, independent molecular biomarker of unfavorable prognosis in CLL. © 2017 Sotirios G. Papageorgiou et al

The design of a promp gamma neutron activation analysis beam for BNCT purpose at the TRIGA Mark II reactor in Pavia.

In preclinical and clinical Boron Neutron Capture Therapy studies the knowledge of the amount of 10B in blood and tissues is very important. The boron concentration measurements method used in Pavia (Italy) is based on the charged particles spectrometry of thin tissue cuts irradiated in the Thermal Column of the TRIGA reactor of the University. In order to perform measurements in biological liquids such as blood and urine, or in other tissue that cannot be cut in slices, a Prompt Gamma Neutron Activation Analysis (PGNAA) [1] facility is being designed, which measures 10B concentration detecting the prompt gamma from boron nuclear capture reaction. At the TRIGA reactor in Pavia, there are four horizontal channels, potentially available for PGNAA. The choice of the suitable channel, and the design of its configuration, were achieved using the Monte Carlo neutron transport code MCNP4c2. To perform the simulations, an input code already validated, describing the reactor structure and the neutron source, was used. The calculations were implemented applying non-analog techniques for the neutron transport, that are necessary to obtain a sufficient statistic in every positions along the channel and especially at its end. The selection of the channel for PGNAA installation was carried out by comparing the simulated fluxes obtained in the different channels at the present configuration. The channel shielded by the core reflector was chosen, because the graphite lowers the fast component of the neutrons, with no need to insert additional material in the facility. The thermal flux at its end is 1.7 x108 n/cm2 s with thermal-to-total neutron flux ratio around 0.8. Subsequently a bismuth block for gamma radiation shielding and blocks of single crystal sapphire as filter for fast neutron component were inserted in the channel. Other components of the facility that are under study are a collimator and the beam catcher

Experimental Study of a Cu-Mo Alloy Vapor Chamber

In this research, the thermal behavior of a vapor chamber embedded in the base of a heat sink was experimentally analyzed considering the influence of the heat source position. The vapor chamber was produced by a copper and molybdenum alloy with length of 240 mm, width of 54 mm, thickness of 3 mm, and capillary structures composed by copper screen meshes. The working fluid used was de-ionized water. The pure aluminum heat sink was cooled by air forced convection and the evaporator vapor chamber was heated using an electrical resistor simulating integrated circuit power dissipation. The experimental tests were done in a suction type wind tunnel with open return for a heat load varying from 20 to 80 W, for an airflow velocity varying from 1 to 4 m/s, and for three different heat source positions. The experimental results showed that, independently of the heat source position, the considered vapor chamber worked successfully, maintaining low operating temperature